SBI Securities’s Moleculin Biotech MBRX Stock Holding History

SBI Securities’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123	Buy	44 +1	+2%	+$3	﹤0.01%	3463
2026 Q1	$98	Buy	43 +14	+48%	+$46	﹤0.01%	3414
2025 Q4	$96	Sell	29 -1	-3%	-$9	﹤0.01%	3417
2025 Q3	$395	Hold	30	–	–	﹤0.01%	3068
2025 Q2	$225	Hold	30	–	–	﹤0.01%	3270
2025 Q1	$726	Buy	30 +14	+88%	+$470	﹤0.01%	2725
2024 Q4	$689	Buy	+16	New	+$969	﹤0.01%	2769

SBI Securities's MBRX Position: Q2 2026 in Review

SBI Securities increased its Moleculin Biotech (MBRX) stake by 2.3% in Q2 2026, buying an estimated $3 and bringing the position to 44 shares worth $123. The position accounts for ﹤0.01% of the portfolio, ranked #3463.

SBI Securities first reported a position in MBRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $726 in Q1 2025. 1 fund tracked by Wall St. Rank holds MBRX as of Q2 2026.

SBI Securities held 44 shares of Moleculin Biotech worth $123 as of Q2 2026.
SBI Securities bought 1 Moleculin Biotech share in Q2 2026, an estimated $3.
Moleculin Biotech made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3463 holding.
SBI Securities first reported a position in Moleculin Biotech in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Moleculin Biotech position peaked at $726 in Q1 2025.
1 fund tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.